Noubar Afeyan
CIK 1222012 · last filed 2026-05-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MRNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MRNA | Director | 2,971,912 | $196.49 | $583.95M | -$1.65B | 95 | 2026-05-22 |
| FHTX | 10%+ Owner | 1,491,441 | $2.02 | $3.02M | $19.20M | 2 | 2024-05-24 |
| SANA | 10%+ Owner | 11,585,199 | $2.44 | $28.27M | $0 | 2 | 2024-02-14 |
| Omega Therapeutics, Inc. (OMGA) Delisted | Director | — | $0.14 | — | $0 | 3 | 2023-06-09 |
| Codiak BioSciences, Inc. (CDAK) Delisted | 10%+ Owner | 1,188,920 | $0.06 | $67.8K | $0 | 1 | 2022-09-16 |
| Rubius Therapeutics, Inc. (RUBY) Delisted | Director | — | $0.08 | — | $0 | 5 | 2022-05-13 |
| TMDX | 10%+ Owner | 0 | $70.35 | $0 | $0 | 1 | 2019-10-31 |
| MCRB | Director | 401,878 | $1.81 | $727.4K | $20.00M | 5 | 2019-06-20 |
| Evelo Biosciences, Inc. (EVLO) Delisted | Director | — | $0.00 | — | $0 | 1 | 2019-06-13 |
| QTRX | 10%+ Owner | 1,443,683 | $2.88 | $4.16M | $0 | 1 | 2017-12-13 |
| EDIT | 10%+ Owner | 2,786,967 | $2.55 | $7.11M | $0 | 1 | 2016-08-15 |
| BG Medicine, Inc. (BGMD) Delisted | Director | 485,002 | — | — | -$4.3K | 4 | 2014-12-05 |
| T2 Biosystems, Inc. (TTOO) Delisted | 10%+ Owner | 475 | $0.00 | $1 | $0 | 1 | 2014-08-14 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Director | — | — | — | $0 | 1 | 2014-03-24 |
| DNIB UNWIND, INC. (BIND) Delisted | Director | 1,542,616 | — | — | $300.0K | 1 | 2013-09-27 |
| HELICOS BIOSCIENCES CORP (HLCS) Delisted | Director | 12,192,640 | — | — | $0 | 6 | 2009-09-22 |
| AGEN | Director | — | $6.24 | — | $0 | 3 | 2007-04-03 |
Recent Filings · Page 12 of 18
178 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-10-28 | MRNA | Sell (S) | −10,000 | -$1.37M | EDGAR |
| 2022-10-21 | MRNA | Sell (S) | −10,000 | -$1.32M | EDGAR |
| 2022-10-14 | MRNA | Sell (S) | −10,000 | -$1.35M | EDGAR |
| 2022-10-07 | MRNA | Sell (S) | −10,000 | -$1.22M | EDGAR |
| 2022-09-30 | MRNA | Sell (S) | −10,000 | -$1.24M | EDGAR |
| 2022-09-23 | MRNA | Sell (S) | −10,000 | -$1.30M | EDGAR |
| 2022-09-16 | Codiak BioSciences, Inc. (CDAK) Delisted | Buy (P) | +3,733,332 | $0 | EDGAR |
| 2022-09-16 | MRNA | Sell (S) | −10,000 | -$1.34M | EDGAR |
| 2022-09-09 | MRNA | Sell (S) | −10,000 | -$1.30M | EDGAR |
| 2022-09-02 | MRNA | Sell (S) | −10,000 | -$1.37M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.